Skip to main content
padlock icon - secure page this page is secure

Outcomes of Bethesda categories III and IV thyroid nodules over 5¬†years and performance of the Afirma gene expression classifier: A single‐institution study

Buy Article:

$52.00 + tax (Refund Policy)

The second edition Bethesda System for Reporting Thyroid Cytology estimates 6%‐18% malignancy rate of category III (B3) and 10%‐40% for category IV (B4) nodules; however, reported malignancy rates have considerable variability among institutions. Use of molecular classifiers (including Afirma Gene Expression Classifier, GEC) can be utilized in management of thyroid nodules. Our objective was to analyse malignancy rates of B3 and B4 nodules and determine clinical outcomes of GEC Benign nodules.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Bethesda; atypia of undetermined significance; gene expression classifier; indeterminate thyroid cytology; molecular marker; suspicious for follicular neoplasm

Document Type: Research Article

Publication date: August 1, 2018

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more